Anavex Life Sciences Corp. (VXL) – Press Releases
-
Vaxil Provides Update on Research Activities and Management Changes
-
Vaxil’s Annual and Special Shareholders Meeting
-
Vaxil Provides Update on Research Activities
-
Vaxil’s Annual and Special Shareholders Meeting
-
Vaxil Provides Final Results on Its Previously Disclosed Research With Ben-Gurion University of the Negev
-
Vaxil Announces Resignation of Director
-
Vaxil Announces Change of Auditor
-
Vaxil Provides Update on Acquisition of Short Wave Pharma Inc.
-
Vaxil Signs Letter of Intent to Acquire a 100% Interest in Short Wave Pharma Inc.
-
Vaxil Announces Progress on Research and Development Activities
-
Vaxil Announces Progress on Research and Development Activities
-
Vaxil Announces Changes to Senior Management and Provides Updates on Current Research and Development Work
-
Vaxil Provides Research and Development Update
-
Vaxil Announces CEO Resignation
-
Vaxil Announces 2021 Reseach and Development Strategy and Progress
-
Vaxil Provides Strategy Update From Conclusion of COVID-19 Challenge Study
-
Vaxil Appoints a Special Advisor to the Board of Directors
-
Vaxil Provides Update on USAMRIID, Oral Experiment and Other General Business Matters
-
Vaxil’s Annual and Special Shareholders Meeting and Update on Exercise of Warrants
-
VAXIL Provides Update on USAMRIID and Oral Experiments
-
Vaxil Retains Investor Engagement and Marketing Firm
-
Vaxil Announces Close of Second and Final Tranche of Previously Announced Non-Brokered Private Placement for Gross Proceeds of $264,100
-
Vaxil Provides Business Update on Corvax™ Experiments
-
Vaxil Announces Close of First Tranche of Previously Announced Non-Brokered Private Placement for Gross Proceeds of $542,858
-
Vaxil Announces Non-Brokered Private Placement
-
Vaxil Enters Into a Cooperative Research and Development Agreement With U.S. Army Medical Research Institute of Infectious Diseases (“USAMRIID”)
-
Vaxil Initiates Pre-Clinical Study in New Oncology Target
-
Vaxil Provides Update of Conversion of Previously Issued Convertible Debt and the Granting of Options
-
Vaxil Announces Positive Results on CorVax™ in vivo Study
-
Vaxil Provides Update on In Vivo Study
-
Vaxil Cancels Brokered Private Placement
-
Vaxil Provides Pre-Clinical and Business Update
-
Vaxil Announces Private Placement Extension
-
Vaxil Announces Brokered Private Placement
-
Vaxil Announces Collaboration Agreement With The Tel Aviv Sourasky Medical Center (Ichilov Hospital), Israel’s Leading Tertiary Care Facility
-
Vaxil Announces Audited Annual Results and Provides Business Update
-
CORRECTION: VAXIL PROVIDES UPDATE ON PRECLINICAL EXPERIMENT
-
Vaxil Provides Update on Preclinical Experiment
-
VAXIL COMMENCES PRECLINICAL COVID-19 VACCINE TRIAL AND FILES AN ADDITIONAL COVID-19 PATENT
-
VAXIL CHANGES WEBSITE DOMAIN NAME, PROVIDES UPDATE ON THE EXERCISE OF WARRANTS AND RECEIVES FINAL TSXV EXCHANGE APPROVAL ON THE DEBENTURE FINANCINGS
-
Vaxil Provides Update Website, Lab Work and the Exercise of Warrants
-
VAXIL APPLIES FOR CORONAVIRUS VACCINE PATENT UNDER ITS ANTI-INFECTIVE VACCINES PLATFORM AND PROVIDES UPDATE ON THE EXERCISE OF WARRANTS
-
Vaxil Announces Closing of Bridge Financing and Provides Update on Corona Virus Vaccine Work
-
Vaxil Announces Financing Update
-
Vaxil Provides Clarification and Further Information on the Possible Identification of a Corona Virus Vaccine
-
Vaxil Announces the Identification of a Potential Corona Virus Vaccine and Provides an Update in the Previously Announced Debt Financing
-
Vaxil Announces Financing Update
-
Vaxil Announces Private Placement Extension
-
Vaxil’s Annual and Special General Meeting
-
Vaxil Announces Private Placement Extension
Back to VXL Stock Lookup
